Download Files:
INCB086550
$460 – $3,600
Products Details
Product Description
– INCB086550 is a potent, oral, small-molecule PD-L1 inhibitor with IC50s value of 3.1, 4.9 and 1.9 nM for human, cynomolgus, and rat, respectively. INCB086550 promotes the dimerization of cell-surface PD-L1 and induces PD-L1 entry into Golgi vesicles then traffick to the nucleus. INCB086550 can be used for multiple cancers research[1].
Web ID
– HY-134884
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C41H39N7O4
References
– [1]WU LIANGXING, et al. BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS. WO2018119266A1.|[2]Koblish HK, et al. Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor. Cancer Discov. 2022 Jun 2;12(6):1482-1499.
CAS Number
– 2230911-59-6
Molecular Weight
– 693.79
Compound Purity
– 98.86
SMILES
– N#CC1=C2C(N=C(C3=C(C(C4=C(C(NC5=NC=CC6=C5N=CC(CN7CC[C@H](C7)O)=C6)=CC=C4)C)=CC=C3)C)O2)=CC(CN8C[C@@H](CC8)C(O)=O)=C1
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– H2O : 83.33 mg/mL (ultrasonic;adjust pH to 3 with HCl)
Target
– PD-1/PD-L1
Pathway
– Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
